Literature DB >> 27654107

Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival.

Abdulrahman Y Hammad1, Nick G Berger1, Dan Eastwood1, Susan Tsai1, Kiran K Turaga1, Kathleen K Christian1, Fabian M Johnston1,2, Timothy M Pawlik2, T Clark Gamblin3.   

Abstract

BACKGROUND: The role of radiotherapy (RT) for surgically resected intrahepatic cholangiocarcinoma (ICC) remains poorly defined. Radiotherapy is often considered when positive resection margins exist. The present study sought to examine the impact of radiotherapy following ICC resection.
METHODS: Patients with early-stage disease, who underwent surgical resection, were identified from the National Cancer Database (1998-2013). Patients were stratified by the receipt of RT. Survival outcomes were examined following propensity score matching (PS), and a Cox regression for survival analysis was used to examine predictors of survival.
RESULTS: A total of 2897 patients were identified. R0 status was achieved in 1951 patients (67.3 %). RT was delivered to 525 patients (R0 = 255, R1/R2 = 230, unknown = 43). Following PS matching, the overall survival for R0 versus R1/R2 resection was 31.2 versus 19.5 months (p < .001), respectively. RT was associated with a trend toward improved survival for R1/R2 lymph node negative patients (39.5 vs. 21.1 months; p = .052). In a multivariate model accounting for different patient and disease characteristics, RT was not associated with survival. In contrast, age, comorbidities, tumor grade, resection margins, lymph nodes status, and tumor's T stage were identified as negative predictors of survival.
CONCLUSIONS: Patients with negative resection margins demonstrated improved survival outcome among ICC patients. In patients with positive resection margins and node negative disease, radiotherapy did not provide a survival benefit. Further studies are warranted to confirm and further define these results.

Entities:  

Mesh:

Year:  2016        PMID: 27654107     DOI: 10.1245/s10434-016-5560-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  Locoregional therapies in cholangiocarcinoma.

Authors:  Peter L Labib; Brian R Davidson; Ricky A Sharma; Stephen P Pereira
Journal:  Hepat Oncol       Date:  2017-11-17

Review 2.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 3.  [Cholangiocarcinoma-Intrahepatic to hilar bile duct cancer].

Authors:  Sebastian Rademacher; Timm Denecke; Thomas Berg; Daniel Seehofer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-13

Review 4.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

Review 5.  The focus clinical research in intrahepatic cholangiocarcinoma.

Authors:  Yinghui Song; Mengting Cai; Yuhang Li; Sulai Liu
Journal:  Eur J Med Res       Date:  2022-07-11       Impact factor: 4.981

6.  Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system.

Authors:  Ze-Wu Meng; Wei Pan; Hai-Jie Hong; Jiang-Zhi Chen; Yan-Ling Chen
Journal:  Oncotarget       Date:  2017-09-15

7.  Modified staging classification for intrahepatic cholangiocarcinoma based on the sixth and seventh editions of the AJCC/UICC TNM staging systems.

Authors:  Ze-Wu Meng; Wei Pan; Hai-Jie Hong; Jiang-Zhi Chen; Yan-Ling Chen
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

8.  The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: A systematic review and meta-analysis.

Authors:  Qiao Ke; Nanping Lin; Manjun Deng; Lei Wang; Yongyi Zeng; Jingfeng Liu
Journal:  PLoS One       Date:  2020-02-21       Impact factor: 3.240

9.  Prognostic Factors and Treatment Strategies for Intrahepatic Cholangiocarcinoma from 2004 to 2013: Population-Based SEER Analysis.

Authors:  Jieqiong Liu; Meizuo Zhong; Yuhua Feng; Shan Zeng; Yikai Wang; Hongbo Xu; Hui Zhou
Journal:  Transl Oncol       Date:  2019-08-22       Impact factor: 4.243

10.  Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma: A multicenter retrospective study.

Authors:  Lei Wang; Manjun Deng; Qiao Ke; Jianying Lou; Shuguo Zheng; Xinyu Bi; Jianming Wang; Wei Guo; Fuyu Li; Jian Wang; Yamin Zheng; Jingdong Li; Shi Cheng; Weiping Zhou; Yongyi Zeng
Journal:  Cancer Med       Date:  2020-02-19       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.